AN2 Therapeutics has entered into a research collaboration with GSK to develop new treatments for tuberculosis (TB).
AN2 Therapeutics與GSK達成了一項研究合作，以開發治療結核病（TB）的新療法。
The Gates Foundation will provide an additional year of funding to support AN2’s work within this partnership.
蓋茨基金會將提供額外一年的資金，以支持 AN2 在此合作伙伴關係中的工作。
Tuberculosis remains one of the world’s most severe health challenges, affecting over a quarter of the global population and causing more than 1.25 million deaths each year. The collaboration aims to develop boron-based leucyl-tRNA synthetase (LeuRS) inhibitors, a new class of compounds targeting novel mechanisms not accessible through conventional carbon-based chemistry..
結核病仍然是全球最嚴峻的健康挑戰之一，影響着全球超過四分之一的人口，每年導致超過125萬人死亡。此次合作旨在開發基於硼的亮氨酰-tRNA合成酶（LeuRS）抑制劑，這是一類針對傳統碳基化學無法觸及的新機制的新型化合物。
AN2’s boron chemistry platform has shown potential in developing drugs for infectious diseases such as nontuberculous mycobacterial (NTM) lung disease and TB. The same validated LeuRS target forms the basis of several compounds, including epetraborole (in development for NTM lung disease), ganfeborole (in development for TB), and tavaborole, an FDA-approved antifungal..
AN2的硼化學平臺在開發治療傳染病（如非結核分枝桿菌（NTM）肺病和結核病）藥物方面顯示出潛力。經驗證的LeuRS靶點是多種化合物的基礎，包括用於治療NTM肺病的在研藥物epetraborole、用於治療結核病的在研藥物ganfeborole，以及獲得FDA批准的抗真菌藥物tavaborole。
This collaboration builds on previous work between AN2’s team and GSK’s Global Health research and development group. It represents a joint effort to explore innovative approaches that could help address the growing burden of TB, particularly in low-income countries.
這項合作建立在AN2團隊與GSK全球健康研發小組之前的工作基礎之上。它代表了一項共同努力，探索創新方法，可能有助於應對結核病日益加重的負擔，特別是在低收入國家。
By combining AN2’s expertise in boron-based drug discovery with GSK’s global health capabilities and continued support from the Gates Foundation, the initiative aims to contribute to the development of new and effective therapies for tuberculosis.
通過結合AN2在硼基藥物發現方面的專業知識與GSK的全球健康能力，以及蓋茨基金會的持續支持，該計劃旨在為結核病開發新的有效療法做出貢獻。
Source: businesswire.com
來源：businesswire.com